Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Disc Medicine Inc IRON

Healthcare Biotechnology
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond... see more

Recent & Breaking News (NDAQ:IRON)

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

GlobeNewswire October 3, 2023

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

GlobeNewswire September 20, 2023

Disc Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire August 30, 2023

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 11, 2023

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

GlobeNewswire July 27, 2023

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire June 22, 2023

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire June 13, 2023

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire June 12, 2023

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

GlobeNewswire June 9, 2023

Disc Medicine to Participate in the Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 15, 2023

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

GlobeNewswire May 11, 2023

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

GlobeNewswire April 21, 2023

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

GlobeNewswire April 13, 2023

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 31, 2023

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

GlobeNewswire March 21, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation

Business Wire February 21, 2023

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

GlobeNewswire February 16, 2023

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

GlobeNewswire February 14, 2023

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

GlobeNewswire February 8, 2023